Welcome to our dedicated page for Surrozen news (Ticker: SRZN), a resource for investors and traders seeking the latest updates and insights on Surrozen stock.
Surrozen reports developments as a clinical-stage biotechnology company developing Wnt-based targeted therapeutics for sight-threatening ophthalmic diseases. Company updates center on its ophthalmology pipeline, including SZN-8141 and SZN-8143 in retinal diseases, antibody-engineering work, financial results, collaboration and license revenue, and research milestones tied to Boehringer Ingelheim.
Recurring announcements also cover healthcare investor conference presentations, Nasdaq inducement equity grants under the 2025 Equity Inducement Plan, and corporate governance or leadership matters that affect the company's public-company reporting profile.
Surrozen, a biotechnology company focused on Wnt pathway modulation, announced that CEO Craig Parker will present at the Stifel 2021 Virtual Healthcare Conference on November 16 at 4:40 p.m. ET. Interested individuals can access the live webcast through the Investors section of Surrozen's website, where a replay will also be available. The company is engaged in developing tissue-specific antibodies aimed at enhancing biological repair mechanisms, targeting diseases like inflammatory bowel disease, hepatitis, and certain neurological disorders. For more details, visit surrozen.com.
Surrozen, Inc. (SRZN) announced encouraging preclinical data supporting the advancement of SZN-1326 for treating inflammatory bowel disease (IBD). Presented during the 2021 United European Gastroenterology Week, the results show significant colonic mucosal healing and epithelial regeneration in various models. SZN-1326 outperformed traditional treatments, indicating its potential as a transformative therapy for conditions like Crohn's disease and ulcerative colitis. The findings emphasize the importance of Wnt signaling in tissue repair. Further studies are planned to explore SZN-1326 in human clinical trials.
Surrozen Inc. (Nasdaq: SRZN) announced the appointment of Elizabeth "Liz" Nguyen as Vice President and Head of Human Resources on September 23, 2021. With over 20 years of HR experience in the biotechnology industry, Nguyen previously held leadership roles at MyoKardia and InterMune. Her expertise is anticipated to enhance Surrozen's organizational development as the company advances its lead programs and broad research pipeline. Craig Parker, CEO, emphasized the timing of her arrival during the company's growth phase.
Surrozen, Inc. has completed its business combination with Consonance-HFW Acquisition Corp., set to commence trading on Nasdaq under the ticker symbols SRZN for common stock and SRZNW for warrants starting August 12, 2021. This merger was approved by the shareholders of both companies, and Surrozen aims to exploit the Wnt pathway for tissue repair. Management, led by CEO Craig Parker, believes this capital infusion will bolster their innovative therapeutic programs.
Surrozen, Inc. has completed its business combination with Consonance-HFW Acquisition Corp., a special purpose acquisition company. The merger was approved by shareholders on August 10, 2021, and will enable Surrozen to trade its shares on Nasdaq under the ticker symbol SRZN and its warrants as SRZNW beginning August 12, 2021. Surrozen aims to unlock therapeutic applications of the Wnt pathway for tissue repair and regeneration, with a management team led by CEO Craig Parker, focusing on developing innovative therapies for serious diseases.
Surrozen Inc. (Nasdaq: SRZN) has announced that CEO Craig Parker will present a company overview and business update at Canaccord Genuity’s 41st Annual Growth Conference on August 12, 2021, at 9:30 a.m. ET. Interested parties can access the live webcast on Surrozen's website, with a replay available afterward.
Surrozen focuses on developing drug candidates that selectively modulate the Wnt pathway, with applications in inflammatory bowel disease, hepatitis, eye diseases, and more. For further details, visit surrozen.com.